Maxaa dhacay
Época Negócios reports that Sam Altman said OpenAI will not conduct an initial public offering in 2026. In an interview with Fortune, the CEO said the company has substantial work ahead on and alignment and that an IPO would currently be imprudent. He also said OpenAI would prefer to remain private while it retains flexibility to pause development if necessary.
Época Negócios says the confirmation came on September 12 from Altman, who told Fortune interviewer Alyson Shontell that OpenAI would not go public in 2026. Altman reportedly said the company has too much to do and that remaining private gives it more freedom while the industry and governments determine how to work together on safety and alignment.
According to the report, Altman described an IPO at this point as imprudent because OpenAI may need to make decisions that are not immediately in shareholders’ interests, including pausing rapid AI development to improve safety and alignment. He said the company does not feel short-term pressure to list and will do so when it is ready.
The report places the decision against earlier expectations that OpenAI was preparing for a possible fourth-quarter 2026 listing. It also cites prior structural steps toward becoming a Public Benefit Corporation, reported valuations above $500 billion at the end of 2025, and Wall Street projections that an IPO could value the company at $1 trillion. These figures and expectations are reported by Época Negócios and are not independently confirmed here.
Faahfaahinta isha: epocanegocios.globo.com ↗
Maxay muhiim u tahay
The decision removes a major expected financial milestone for one of the most valuable AI companies and links OpenAI’s corporate structure directly to decisions about how quickly it develops increasingly capable systems. Altman’s explanation suggests that safety considerations, regulatory coordination and the ability to delay development may take priority over near-term shareholder pressures, although the report does not establish how those commitments will be implemented or evaluated.
OpenAI’s choice matters because access to public capital can bring scrutiny and shareholder demands that may conflict with decisions to slow or pause development. Altman’s stated rationale presents private ownership as a way to preserve discretion during a period when the company expects AI capabilities, regulation and safety practices to change rapidly.
The report also says OpenAI and Anthropic publicly committed on the same day to slow model development and supported external monitoring of whether their systems are being developed responsibly. The source does not provide a timetable, enforcement mechanism, technical or independent assessment showing that either company has actually reduced its development pace.
The report’s account does not independently verify the cited valuations, prediction-market movements, Anthropic’s reported IPO preparations or the practical effect of OpenAI’s corporate structure. It also does not establish whether remaining private will materially improve safety outcomes.
Farsamaynta Is-dhexgalka: Sida Dhabta Ay U Shaqeyso
U baadh tignoolajiyada hoose ee ka dambeeya horumarkan si isdhexgal leh.
Why can ethical evaluation not be reduced to one model score?
Maxaa la daawan doona xiga
The timing of any future IPO remains unknown. Watch for further changes to OpenAI’s corporate structure, clearer third-party monitoring arrangements, and evidence of whether the company or other AI labs actually slow model development as regulations and safety protocols advance.
No future IPO date or alternative financing timetable is provided. Altman’s statement leaves open when OpenAI might consider going public and what conditions would make the company consider itself ready.
The source says OpenAI will allow external parties to monitor responsible development, but it does not identify the monitors, their authority, the information they will receive or how their findings will be published.
The main practical question is whether OpenAI’s stated flexibility produces observable changes, such as delayed releases, stronger safety testing or documented pauses. The report provides no evidence yet that such measures have occurred.